Sheep aphthovirus Asial type multi-epitope recombinant vaccine and preparation method thereof

Abstract

The invention discloses a sheep aphthovirus Asial type multi-epitope recombinant vaccine and a preparation method thereof. The recombinant vaccine comprises the following ingredients: a protein encoded by aphthovirus multi-epitope genes and carrier protein fusion genes, and an aphthovirus 3D protein. The preparation method comprises the following steps: respectively diluting the protein encoded by the aphthovirus multi-epitope genes and the carrier protein fusion genes and the aphthovirus 3D protein; then, uniformly mixing the diluted proteins; adding auxiliary agents into the mixture; carrying out emulsification; and obtaining the sheep aphthovirus Asia1 type multi-epitope recombinant vaccine. Animal model and animal immune efficiency experiments show that the sheep Asial epitope recombinant vaccine of the invention can generate overall immunoprotection reaction, injected immune sheep can be induced to generate high-level neutralizing antibodies, and can also induce the cellullar immunologic response. The recombinant vaccine of the invention can effectively protect animals from the virulent strain attack of the aphthovirus.

Description

technical field [0001] The invention relates to an animal recombinant vaccine, in particular to a Asia1 multi-epitope recombinant vaccine of sheep foot-and-mouth disease virus and a preparation method thereof, belonging to the field of sheep foot-and-mouth disease virus recombinant vaccine. Background technique [0002] As a major animal disease, foot-and-mouth disease not only seriously threatens the healthy development of animal husbandry, but also causes a series of social problems such as people's worries about food safety. Vaccine immunization is still one of the main means to effectively prevent and control FMD. However, most of the currently used vaccines are inactivated vaccines developed from pathogens. The production of such vaccines not only requires a high-level biosafety production workshop to prevent pathogens from escaping, but also requires a distinction between vaccine immunity and naturally infected animals. In addition, incomplete virus inactivation has t...

AI Technical Summary

Problems solved by technology

However, the large-scale animal experiments all ended in failure (the protection rate of the virus attack did not reach the national standard), mainly because the small molecule antigens developed could not stimulate the body to produce a protective level of neutralizing antibodies, and some even could produce a certain level of protection. Antibodies, but the duration is short, which cannot meet the needs of epidemic prevention and control

In addition, the developed virus particle-like capsid protein can induce the body to produce high-titer protective antibodies, and immunized animals can resist the challenge of homologous viruses, but the low yield and high cost of the antigen limit the application of the vaccine

Recently, people have increased the immunogenicity of vaccines by increasing T cell epitopes and foreign carrier proteins to enhance antigen presentation capabilities, increase molecular wei

Images